CD274 and melanoma: However, considering that anti-CTLA-4 monotherapy comes with higher toxicity and lower response rates than anti-PD-(L)1 (according to comparative clinical trials in melanoma patients [165,166]), increasing number of studies have focused on targeting the PD-1/PD-L1 pathway.